Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.60 |
| ▸ | EED | O75530 | 1/20 | 0.60 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.60 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.60 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.60 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13276540 | 1.00 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13277238 | 0.91 | EZH2 (0.51) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL18829912 | 0.90 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL30499098 | 0.89 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13280854 | 0.89 | EZH2 (0.49) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL24072862 | 0.88 | EZH2 (0.47) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL29448162 | 0.87 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13276957 | 0.87 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15864840 | 0.87 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16935249 | 0.87 | EZH2 (0.49) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| CN-113330008-B | Preparation method of amide compound and application of amide compound in medicine field | 上海华汇拓医药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-115197202-B | EZH2 covalent inhibitor and preparation method and application thereof | 四川大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4140487-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme Inc (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115197202-A | EZH2 covalent inhibitor and preparation method and application thereof | 四川大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20220281854-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-11370781-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-2836216-B1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2022-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-11370781-B2 | Combination therapy for treating cancer | EZH2, BMI1, HDAC2 | EZH2 1/4885EED 14/4885RBBP4 78/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20220281854-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, BMI1, HDAC2 | EZH2 1/4885EED 14/4885RBBP4 78/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.